{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:16:35Z","timestamp":1790270195715,"version":"4.1.0"},"reference-count":28,"publisher":"National Academy of Sciences","issue":"36","license":[{"start":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T00:00:00Z","timestamp":1519171200000},"content-version":"vor","delay-in-days":184,"URL":"http:\/\/www.pnas.org\/site\/misc\/userlicense.xhtml"}],"funder":[{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI44616"],"award-info":[{"award-number":["AI44616"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"HHS | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["GM32136"],"award-info":[{"award-number":["GM32136"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"HHS | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["GM49551"],"award-info":[{"award-number":["GM49551"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI122864"],"award-info":[{"award-number":["AI122864"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2017,9,5]]},"abstract":"<jats:title>Significance<\/jats:title>\n                  <jats:p>HIV-1 reverse transcriptase (RT) has been the prime target for anti-HIV chemotherapy; however, its rapid mutation often generates drug resistance. Prominent variant strains of HIV-1 that lead to treatment failure with nonnucleoside RT inhibitors (NNRTIs) bear the Tyr181Cys mutation in RT. Based on our previous discovery and crystallography for potent noncovalent NNRTIs, new compounds were designed with incorporation of chemical warheads intended to modify covalently Cys181. Here we report on the success of the strategy, including biochemical, biophysical, and cellular evidence of the desired irreversible covalent inhibition. The new compounds completely eliminate the activity of Cys181-bearing RT, and it may be possible to dose them less frequently than noncovalent inhibitors.<\/jats:p>","DOI":"10.1073\/pnas.1711463114","type":"journal-article","created":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T20:40:20Z","timestamp":1503348020000},"page":"9725-9730","update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":52,"title":["Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallography"],"prefix":"10.1073","volume":"114","author":[{"given":"Albert H.","family":"Chan","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520-8066;"},{"name":"Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, CT 06520-8066;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Gil","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Yale University, New Haven, CT 06520-8107"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krasimir A.","family":"Spasov","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520-8066;"},{"name":"Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, CT 06520-8066;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Cisneros","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Yale University, New Haven, CT 06520-8107"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalley N.","family":"Kudalkar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520-8066;"},{"name":"Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, CT 06520-8066;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaritza O.","family":"Petrova","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520-8066;"},{"name":"Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, CT 06520-8066;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda B.","family":"Buckingham","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520-8066;"},{"name":"Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, CT 06520-8066;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520-8066;"},{"name":"Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, CT 06520-8066;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3993-9520","authenticated-orcid":false,"given":"William L.","family":"Jorgensen","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Yale University, New Haven, CT 06520-8107"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2017,8,21]]},"reference":[{"key":"e_1_3_4_1_2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrd.2016.69","article-title":"The HIV therapy market","volume":"15","author":"Gubernick SI","year":"2016","unstructured":"SI Gubernick, N F\u00e9lix, D Lee, JJ Xu, B Hamad, The HIV therapy market. Nat Rev Drug Discov 15, 451\u2013452 (2016).","journal-title":"Nat Rev Drug Discov"},{"key":"e_1_3_4_2_2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/1060028016682531","article-title":"Single-tablet regimens for the treatment of HIV-1 infection","volume":"51","author":"Sebaaly JC","year":"2017","unstructured":"JC Sebaaly, D Kelley, Single-tablet regimens for the treatment of HIV-1 infection. Ann Pharmacother 51, 332\u2013344 (2017).","journal-title":"Ann Pharmacother"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.3390\/v6104095","article-title":"Current perspectives on HIV-1 antiretroviral drug resistance","volume":"6","author":"Iyidogan P","year":"2014","unstructured":"P Iyidogan, KS Anderson, Current perspectives on HIV-1 antiretroviral drug resistance. Viruses 6, 4095\u20134139 (2014).","journal-title":"Viruses"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.antiviral.2009.09.008","article-title":"Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989\u20132009)","volume":"85","author":"de B\u00e9thune MP","year":"2010","unstructured":"MP de B\u00e9thune, Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989\u20132009). Antiviral Res 85, 75\u201390 (2010).","journal-title":"Antiviral Res"},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"15686","DOI":"10.1021\/ja2058583","article-title":"Efficient discovery of potent anti-HIV agents targeting the Tyr181Cys variant of HIV reverse transcriptase","volume":"133","author":"Jorgensen WL","year":"2011","unstructured":"WL Jorgensen, , Efficient discovery of potent anti-HIV agents targeting the Tyr181Cys variant of HIV reverse transcriptase. J Am Chem Soc 133, 15686\u201315696 (2011).","journal-title":"J Am Chem Soc"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.bmcl.2012.11.115","article-title":"Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency","volume":"23","author":"Bollini M","year":"2013","unstructured":"M Bollini, , Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency. Bioorg Med Chem Lett 23, 1110\u20131113 (2013).","journal-title":"Bioorg Med Chem Lett"},{"key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1021\/jm040840e","article-title":"In search of a novel anti-HIV drug: Multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)","volume":"48","author":"Janssen PA","year":"2005","unstructured":"PA Janssen, , In search of a novel anti-HIV drug: Multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem 48, 1901\u20131909 (2005).","journal-title":"J Med Chem"},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1021\/acsmedchemlett.6b00390","article-title":"Design, conformation, and crystallography of 2-naphthyl phenyl ethers as potent anti-HIV agents","volume":"7","author":"Lee WG","year":"2016","unstructured":"WG Lee, AH Chan, KA Spasov, KS Anderson, WL Jorgensen, Design, conformation, and crystallography of 2-naphthyl phenyl ethers as potent anti-HIV agents. ACS Med Chem Lett 7, 1156\u20131160 (2016).","journal-title":"ACS Med Chem Lett"},{"key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh J","year":"2011","unstructured":"J Singh, RC Petter, TA Baillie, A Whitty, The resurgence of covalent drugs. Nat Rev Drug Discov 10, 307\u2013317 (2011).","journal-title":"Nat Rev Drug Discov"},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"13408","DOI":"10.1002\/anie.201601091","article-title":"Targeted covalent inhibitors for drug design","volume":"55","author":"Baillie TA","year":"2016","unstructured":"TA Baillie, Targeted covalent inhibitors for drug design. Angew Chem Int Ed Engl 55, 13408\u201313421 (2016).","journal-title":"Angew Chem Int Ed Engl"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1021\/jm3003203","article-title":"Irreversible protein kinase inhibitors: Balancing the benefits and risks","volume":"55","author":"Barf T","year":"2012","unstructured":"T Barf, A Kaptein, Irreversible protein kinase inhibitors: Balancing the benefits and risks. J Med Chem 55, 6243\u20136262 (2012).","journal-title":"J Med Chem"},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1021\/ja00221a020","article-title":"Cis trans energy difference for the peptide-bond in the gas-phase and in aqueous-solution","volume":"110","author":"Jorgensen WL","year":"1988","unstructured":"WL Jorgensen, J Gao, Cis trans energy difference for the peptide-bond in the gas-phase and in aqueous-solution. J Am Chem Soc 110, 4212\u20134216 (1988).","journal-title":"J Am Chem Soc"},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1039\/b307800k","article-title":"Synthesis and evaluation of new potential HIV-1 non-nucleoside reverse transcriptase inhibitors. New analogues of MKC-442 containing Michael acceptors in the C-6 position","volume":"1","author":"Petersen L","year":"2003","unstructured":"L Petersen, CH Jessen, EB Pedersen, C Nielsen, Synthesis and evaluation of new potential HIV-1 non-nucleoside reverse transcriptase inhibitors. New analogues of MKC-442 containing Michael acceptors in the C-6 position. Org Biomol Chem 1, 3541\u20133545 (2003).","journal-title":"Org Biomol Chem"},{"key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s00706-006-0548-3","article-title":"Synthesis and anti-HIV-1 activity of novel MKC-442 analogues containing alkenyl chains or reactive functionalities in the 6-benzyl group","volume":"137","author":"Aly YL","year":"2006","unstructured":"YL Aly, EB Pedersen, P La Colla, R Loddo, Synthesis and anti-HIV-1 activity of novel MKC-442 analogues containing alkenyl chains or reactive functionalities in the 6-benzyl group. Monatsh Chem 137, 1557\u20131570 (2006).","journal-title":"Monatsh Chem"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0006-2952(94)90002-7","article-title":"Antiviral activity of 2\u2032,3\u2032-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2\u2032,3\u2032-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro","volume":"47","author":"Lin TS","year":"1994","unstructured":"TS Lin, , Antiviral activity of 2\u2032,3\u2032-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2\u2032,3\u2032-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro. Biochem Pharmacol 47, 171\u2013174 (1994).","journal-title":"Biochem Pharmacol"},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1128\/AAC.46.3.887-891.2002","article-title":"Novel use of a guanosine prodrug approach to convert 2\u2032,3\u2032-didehydro-2\u2032,3\u2032-dideoxyguanosine into a viable antiviral agent","volume":"46","author":"Ray AS","year":"2002","unstructured":"AS Ray, Z Yang, CK Chu, KS Anderson, Novel use of a guanosine prodrug approach to convert 2\u2032,3\u2032-didehydro-2\u2032,3\u2032-dideoxyguanosine into a viable antiviral agent. Antimicrob Agents Chemother 46, 887\u2013891 (2002).","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1021\/acsmedchemlett.5b00254","article-title":"Potent inhibitors active against HIV reverse transcriptase with K101P, a mutation conferring rilpivirine resistance","volume":"6","author":"Gray WT","year":"2015","unstructured":"WT Gray, , Potent inhibitors active against HIV reverse transcriptase with K101P, a mutation conferring rilpivirine resistance. ACS Med Chem Lett 6, 1075\u20131079 (2015).","journal-title":"ACS Med Chem Lett"},{"key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1021\/jm501908a","article-title":"Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants","volume":"58","author":"Frey KM","year":"2015","unstructured":"KM Frey, , Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants. J Med Chem 58, 2737\u20132745 (2015).","journal-title":"J Med Chem"},{"key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"7334","DOI":"10.1021\/bi052362v","article-title":"Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations","volume":"45","author":"Basavapathruni A","year":"2006","unstructured":"A Basavapathruni, , Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations. Biochemistry 45, 7334\u20137340 (2006).","journal-title":"Biochemistry"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1073\/pnas.0711209105","article-title":"High-resolution structures of HIV-1 reverse transcriptase\/TMC278 complexes: Strategic flexibility explains potency against resistance mutations","volume":"105","author":"Das K","year":"2008","unstructured":"K Das, , High-resolution structures of HIV-1 reverse transcriptase\/TMC278 complexes: Strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci USA 105, 1466\u20131471 (2008).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","article-title":"Processing of X-ray diffraction data collected in oscillation mode","volume":"276","author":"Otwinowski Z","year":"1997","unstructured":"Z Otwinowski, W Minor, Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276, 307\u2013326 (1997).","journal-title":"Methods Enzymol"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1107\/S0907444909047337","article-title":"Xds","volume":"66","author":"Kabsch W","year":"2010","unstructured":"W Kabsch, Xds. Acta Crystallogr D Biol Crystallogr 66, 125\u2013132 (2010).","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: A comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams PD","year":"2010","unstructured":"PD Adams, , PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1021\/ml5003713","article-title":"Picomolar inhibitors of HIV-1 reverse transcriptase: Design and crystallography of naphthyl phenyl ethers","volume":"5","author":"Lee WG","year":"2014","unstructured":"WG Lee, , Picomolar inhibitors of HIV-1 reverse transcriptase: Design and crystallography of naphthyl phenyl ethers. ACS Med Chem Lett 5, 1259\u20131262 (2014).","journal-title":"ACS Med Chem Lett"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of coot","volume":"66","author":"Emsley P","year":"2010","unstructured":"P Emsley, B Lohkamp, WG Scott, K Cowtan, Features and development of coot. Acta Crystallogr D Biol Crystallogr 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1107\/S0907444908004319","article-title":"Iterative-build OMIT maps: Map improvement by iterative model building and refinement without model bias","volume":"64","author":"Terwilliger TC","year":"2008","unstructured":"TC Terwilliger, , Iterative-build OMIT maps: Map improvement by iterative model building and refinement without model bias. Acta Crystallogr D Biol Crystallogr 64, 515\u2013524 (2008).","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"e_1_3_4_27_2","unstructured":"WL DeLano PyMOL molecular viewer: Updates and refinements. Abstr Pap Am Chem Soc 238 (abstr). (2009)."},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","first-page":"e01456","DOI":"10.7554\/eLife.01456","article-title":"Collaboration gets the most out of software","volume":"2","author":"Morin A","year":"2013","unstructured":"A Morin, , Collaboration gets the most out of software. Elife 2, e01456 (2013).","journal-title":"Elife"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.pnas.org\/syndication\/doi\/10.1073\/pnas.1711463114","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.1711463114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T12:05:02Z","timestamp":1654603502000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1711463114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,21]]},"references-count":28,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2017,9,5]]}},"alternative-id":["10.1073\/pnas.1711463114"],"URL":"https:\/\/doi.org\/10.1073\/pnas.1711463114","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,21]]},"assertion":[{"value":"2017-08-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}